Cyprotex, a global provider of complete range of preclinical ADME Tox services, has declared the release of Cyprotox, a new service which uses automated methods for a better understanding of the mechanisms of drug toxicity.
An additional space of 90 sq m has been allotted to the laboratory at Cyprotex's Macclesfield, UK, in order to provide the same facilities as those of Apredica, MA in USA which was formerly acquired by Cyprotek on 6th August 2010.
One of the toxicology services provided under Cyprotox is an ArrayScan(R) VTI HCS Reader which balances the four HCS instruments used at Areca. It uses High Content Screening technology to capture the key markers involved in cellular toxicity. Unlike traditional toxicology determination methods, HCS has been thoroughly validated by its extensive use in pharmaceutical industries. The other services offered by Cyprotox include screening of reactive metabolites, evaluation of mitochondrial toxicity, identifying inhibitors for human ether-a-go-go related gene (hERG), monitoring a wide range of different toxicologically relevant genes, phospholipidosis; haemolysis, investigating drug to drug interactions and assessing genotoxicity and phototoxicity.
According to Dr Anthony Baxter, Cyprotex's Chief Executive Officer, the major hindrance faced by drug development is toxicity, which can be improved significantly by identifying the possible reasons behind cell toxicity at the initial stage itself. Cyprotox, along with the existing ADME business can benefit customers in terms of cost-effective and high quality predictive modeling and CellCiphr technology obtained from Cellumen.